A structure and application of fluorescent probe-based detection for pre-transfusion
Through the interlaced runner design based on fluorescent probes and paper-based chips, combined with ionic aggregation-induced luminescent materials, the problem of large-scale equipment dependence and low detection accuracy in the prior art is solved, and fast and accurate blood sample detection is achieved , suitable for outdoor emergency rescue.
Patent Information
- Application Number
- CN202410321950.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-20
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-03-20
AI Technical Summary
The existing clinical blood type detection technology relies on large equipment and cannot meet the needs of outdoor emergency rescue. It also has low accuracy in detection of complex samples and is prone to interference from background signals, resulting in misjudgment.
Using a fluorescent probe-based structure, using interlaced runner design and paper-based chips, combined with ionic aggregation-induced luminescent materials such as TTVP and TTPy, the blood type and albumin concentration can be determined through the fluorescence signal response, and the rapid and accurate blood sample detection can be achieved. .
It realizes fast and accurate blood sample detection without relying on large equipment. Through fluorescence resonance energy transfer and specific fluorescence response, it improves detection efficiency and accuracy, reduces interference, and is suitable for outdoor emergency use.
Smart Images

Figure CN118190888B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical detection, and in particular to a structure and application of a fluorescent probe-based detection device for pre-transfusion detection. Background Art
[0002] The existing clinical blood type detection technology is mainly based on serology, including the slide method, microplate method, test tube method and microcolumn gel method, etc. The main principle is to observe the agglutination of red blood cells after the specific antigen-antibody reaction. The slide method is simple to operate and fast to detect, and is often used in the initial screening of blood transfusion compatibility detection. As clinical standard methods, the test tube method and microcolumn gel method are more sensitive and reliable than the slide method. However, the professional requirements for operators are high, and there are still difficulties in realizing the rapid identification of weakly agglutinated blood types. The above-mentioned technology still relies on large centrifugal equipment, which is bulky and cannot meet the requirements of outdoor emergency rescue. Existing research is based on paper-based microfluidics for blood type detection and analysis, but it is easily interfered by complex samples, often causing misjudgment of results, resulting in low accuracy. The background signal in complex samples has great interference with the detection of most clinical blood or serum samples, which seriously affects the determination of test data. It is urgent to develop a new type of mechanism or device that does not rely on large equipment, is easy to carry, and can quickly and accurately realize blood sample detection, which has met the needs of clinical practice. Summary of the invention
[0003] The present invention is intended to provide a structure based on fluorescent probes for pre-transfusion detection to solve the technical problem that the prior art lacks a device that does not rely on large equipment, is easy to carry, and can quickly and accurately perform blood sample detection.
[0004] In order to achieve the above object, the present invention adopts the following technical scheme:
[0005] A structure for pre-transfusion detection based on fluorescent probes includes a detection flow channel; the detection flow channel includes a blood sample mixing flow channel and a color development part arranged in sequence according to the flow direction of the blood sample; the blood sample mixing flow channel is coated with a blood type detection reagent, and the color development part is coated with an ionic aggregation-induced luminescence material.
[0006] Furthermore, the ionic aggregation-induced emission material is TTVP and / or TTPy.
[0007] Furthermore, the blood type detection reagent is one of red blood cell A reagent, red blood cell B reagent, anti-A reagent, anti-B reagent, anti-D reagent, anti-C reagent, anti-c reagent, anti-E reagent and anti-e reagent.
[0008] Furthermore, a paper-based chip is provided in the detection flow channel; the blood sample mixing flow channel includes ≥3 curved flow channels, and the curved flow channels are arranged in sequence according to the direction of blood sample flow; and the blood type detection reagent is coated in the first two curved flow channels.
[0009] Furthermore, the blood sample mixing flow channel includes a first direct current channel, a second direct current channel to an N-1th direct current channel, and an Nth direct current channel which are arranged and connected in sequence according to the flow direction of the blood sample; a first curved flow channel is connected between the first direct current channel and the second direct current channel, and an N-1th curved flow channel is connected between the N-1th direct current channel and the Nth direct current channel; an angle between the N-1th direct current channel and the Nth direct current channel is 45-60°; N≥4.
[0010] Furthermore, the width of the blood sample mixing channel is 1mm-5mm and the depth is 1mm-5mm; the diameter of the color developing part is 4-8mm and the depth is 1mm-5mm; the length of the detection channel is 20mm-50mm and the width is 5mm-25mm.
[0011] Furthermore, the concentration of the ionic aggregation-induced emission material coated in the color development part is 60-100 μM.
[0012] Furthermore, the detection flow channel is arranged on a rotatable base layer; the number of the detection flow channels is several and they are centrally symmetrically distributed around the center of the base layer; the end of the blood sample mixing flow channel away from the color development part is connected to a sample addition hole.
[0013] This solution also provides the use of ionic aggregation-induced luminescence materials in preparing blood type detection structures or in detecting albumin concentrations, wherein the ionic aggregation-induced luminescence materials are TTVP and / or TTPy.
[0014] Furthermore, the ionic aggregation-induced luminescence material is used to bind to albumin in a blood sample treated with a blood type detection reagent and generate a fluorescent signal under excitation; the blood type is determined by the value of the fluorescent signal and the type of the blood type detection reagent.
[0015] In summary, the principles and beneficial effects of the present invention are:
[0016] In this technical solution, a specific design of staggered flow channels is adopted, and antibodies or red blood cell reagents are pre-coated at the bends. When the whole blood sample to be tested passes through the paper-based flow channel, it will mix and react with the pre-coated reagents and then flow into the next detection area. A certain amount of fluorescent probes, such as TTVP and / or TTPy, are pre-coated in the detection area, and the blood type and albumin content are determined based on the different degrees of fluorescence response of the fluorescent probe TTVP with whole blood, red blood cells, and plasma.
[0017] The beneficial effects of this technical solution are summarized as follows:
[0018] (1) The fluorescent probe specifically binds to albumin in serum. According to the properties of AIE, the system will produce fluorescence resonance energy transfer after the two bind, thereby achieving accurate quantification of albumin.
[0019] (2) Whole blood contains plasma and blood cells. When blood cells are not broken, they block fluorescence to a certain extent. The fluorescence value of the fluorescent probe responding to whole blood is much lower than the fluorescence value corresponding to plasma fluorescence. Therefore, blood type can be determined based on the fluorescence value.
[0020] (3) The paper-based flow channel is designed as a staggered flow channel. By taking advantage of the increased resistance and reduced flow rate of the fluid at the bend, the material pre-coated at the bend can fully react with the components in the sample. Combined with the driving force and centrifugal force, the effect of full mixing can be achieved.
[0021] (4) The capillary action of the paper base in the detection device and the driving force of the fingertip of the detection device are used to drive the sample to move and achieve the detection purpose. In addition, the self-rotation characteristics of the device can shorten the detection time and accelerate the detection process.
[0022] (5) In addition to TTVP, TTPy can also be used as an alternative fluorescent probe. Currently, only these two fluorescent probes have been found to be applicable to blood type and protein detection.
[0023] (6) The optimal intersection angle of the staggered flow channel is 45°-55°, and the optimal TTVP concentration is 60-100 μM. Using the above parameters can improve detection efficiency, reduce interference, and improve detection accuracy. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 1 and 2 are the absorption spectrum and emission spectrum of TTVP of Example 1.
[0025] Figure 2 Graphs 1 and 2 show the photoluminescence spectra of the TTVP of Example 1 in different samples.
[0026] Figure 3 The fluorescence intensity of the emitted light of different fluorescent materials in Example 1 in whole blood, plasma and red blood cell samples.
[0027] Figure 4 This is the specific response phenomenon between the fluorescent dye of Example 2 (taking TTVP as an example) and albumin in plasma.
[0028] Figure 5 The fluorescence curves of Example 2 are those of the fluorescent dye (taking TTVP as an example) and different albumin concentrations.
[0029] Figure 6This is a front view of the detection structure of Example 3.
[0030] Figure 7 This is a side view of the detection structure of Example 3.
[0031] Figure 8 Schematic diagram of the detection channel distribution of Example 3.
[0032] Fig. 9 This is a front view of the detection channel of Example 3.
[0033] Fig.10 This is a statistical chart of typical sample detection results in Example 3.
[0034] Fig.11 It is a front view of the detection channel of Example 4 (single-bend pipeline).
[0035] Fig.12 It is a front view of the detection channel of Example 4 (double-bend pipe).
[0036] Fig.13 It is a front view of the detection channel of Example 4 (straight pipe). DETAILED DESCRIPTION
[0037] The present invention is further described in detail below in conjunction with examples, but the embodiments of the present invention are not limited thereto. Unless otherwise specified, the technical means used in the following examples and experimental examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used can be obtained from commercial sources.
[0038] The specific reference numerals are as follows: base layer 1, sample addition hole 2, detection channel 3, first direct current channel 4, second direct current channel 5, third direct current channel 6, fourth direct current channel 7, color development hole 8, first curved flow channel 9, second curved flow channel 10, third curved flow channel 11, protection plate 12, sample addition port 13, connecting ring 14, rotating shaft 15, bearing 16.
[0039] Embodiment 1:
[0040] TTVP (Tetraphenylethylene-Triphenylamine-Vinylene-Phenylene) is an ionic aggregation-induced emission (AIE) material, named as:
[0041] (E)-4-(2-(5-(4-(diphenylamino)phenyl)thiophen-2-yl)vinyl)-1-(3-(trimethylammonio)propyl)pyridin-1-ium bromide.
[0042] This material can be obtained through commercial means, for example, Xi'an Qiyue Biological Company, Chemical Hui, etc. can provide this material. For TTVP, Reaxys ID is 32697862; chemical formula: 2Br*C 35 H37N3S; molecular weight: 691.573; linear structural chemical formula: C 35 H 37 N3S (2+) *2Br (1-) ; InChIKey: DDHNNXUVOBOUNC-UHFFFAOYSA-M. The structure, general properties and synthesis method of TTVP can be found in the literature: "Xueni Huang, Seeing is believing: Efficiency evaluation of multifunctional ionic-dependent AIEgens for tuberculosis, Biomaterials, 2023".
[0043] TTVP is a compound containing tetraphenylethylene, triphenylamine, ethylene and benzene rings. These structural units together constitute a material with aggregation-induced emission properties. Due to its special structure and properties, TTVP can emit red fluorescence in aqueous solution. This makes it have potential application value in the fields of bioimaging, fluorescent probes, biosensors and analysis. The absorption and emission spectra of TTVP are detailed in Figure 1 , with a maximum absorption value at about 480 nm and a maximum emission value at about 675 nm.
[0044] This example tests the fluorescence color development effect of TTVP on blood samples. Take a blank centrifuge tube, add 500 μL of whole blood, plasma and red blood cells as samples respectively, and add samples and 100 μM TTVP solution in a ratio of 1:4-1:8 (in the specific experiment, the volume ratio of the sample and the TTVP solution is 1:6). Since the reaction between the sample and the TTVP solution can be carried out instantaneously, subsequent detection can be carried out after mixing. Set the emission wavelength to 480 nm, use a fluorescence spectrophotometer to measure the fluorescence value, extract the fluorescence value at the maximum peak, repeat the above operation three times, and the photoluminescence spectrum is detailed in Figure 2 The results showed that the fluorescence intensity detected by the system with red blood cells and TTVP reaction was the lowest; the fluorescence intensity detected by the system with plasma and TTVP reaction was the highest; the fluorescence intensity detected by the system with whole blood and TTVP reaction was between the response values of plasma and red blood cells and TTVP. Figure 2The spectrum shows that the peak of the fluorescence emission peak of the system with plasma and TTVP reaction is prominent, the peak of the fluorescence emission peak of the system with whole blood and TTVP reaction is relatively gentle, and it is basically difficult to observe the emission peak of the system with blood cells and TTVP reaction. The inventor analyzed that the reason is that there are some substances in plasma that promote TTVP aggregation and emit fluorescence, while blood cells do not have the above substances that promote TTVP aggregation, and it is possible that red blood cells have a certain inhibitory effect on the aggregation of TTVP and block fluorescence to a certain extent, thus causing different fluorescence response patterns between whole blood and plasma and fluorescent probes. Therefore, this discovery can be used as a strong support for fluorescent probes to distinguish the three components of plasma, whole blood, and red blood cells.
[0045] TTVP and TTPy are composed of triphenylamine fragments (acting as electron donors), thiophene units (acting as electron donors and π bridges), carbon-carbon double bonds, and different pyridine moieties (acting as electron acceptors), and the pyridine moieties have different degrees of electronic DA and T conjugation. The presence of robust DA effects and extended π-conjugation in TTVP and TTPy indicates that they can emit long-wavelength fluorescence. In addition to TTVP, the inventors also tried TTPy and found that it showed similar phenomena to TTVP for whole blood, plasma, and red blood cells, that is, the fluorescence detected in the system with red blood cells and TTVP reaction was the lowest; the fluorescence intensity of the system with TTVP reaction was significantly improved when plasma was added; and the fluorescence of whole blood was between the response values of plasma and red blood cells and TTVP. Therefore, both TTVP and TTPy can be used to indicate whether red blood cells block the fluorescence signal, and then distinguish the three components of plasma, whole blood, and red blood cells. The detection of blood type before transfusion is mainly based on the agglutination of blood cells under different conditions. Therefore, TTVP and TTPy can be used to indicate blood type.
[0046] Specifically, the systematic name of TTPy (triphenylamine thiophen pyridinium) is:
[0047] (E)-4-(2-(5-(4-(diphenylamino)phenyl)thiophen-2-yl)vinyl)-1-propylpyridin-1ium.
[0048] The structure, general properties and synthesis methods of TTPy can be found in the literature: "Xueni Huang, Seeing is believing: Efficiency evaluation of multifunctional ionic-dependent AIEgens for tuberculosis, Biomaterials, 2023".
[0049] In addition to the two aggregation-induced luminescence materials TTVP and TTPy, the inventors have also tried other aggregation-induced luminescence materials, such as tetraphenylethylene-azide aggregation-induced luminescence material (CAS: 1403677-99-5), tetracarboxytetraphenylethylene, 4-(1,2,2-triphenylvinyl)benzoic acid (CAS: 197153-87-0), etc. The experimental method refers to the aforementioned experiment of mixing plasma, whole blood, and red blood cells with aggregation-induced luminescence materials to detect the emission fluorescence intensity. The three aggregation-induced luminescence materials, tetraphenylethylene-azide, tetracarboxytetraphenylethylene or its sodium salt, and 4-(1,2,2-triphenylvinyl)benzoic acid, have different response effects on plasma, whole blood, and red blood cells than TTVP and TTPy. Specifically, after adding plasma, whole blood, and red blood cells, these three candidate materials all show similar photoluminescence spectra, similar to Figure 2 That is, the three candidate materials all showed no difference in response to plasma, whole blood and red blood cells. The inventors analyzed that the reason was that the three candidate materials could not bind to plasma or blood cells, and thus could not produce the effect of aggregated luminescence. Figure 3 , showing the fluorescence value statistics of the above three fluorescent materials at the emission peak under the optimal excitation wavelength. Therefore, although these three materials are aggregation-induced emission materials, the fluorescence values of the emission peaks for plasma, whole blood, and red blood cells are not significantly different, so they cannot be used to distinguish plasma, whole blood, and red blood cells. Compared with other aggregation-induced emission materials, TTVP and TTPy used in this scheme have unique effects in distinguishing plasma, whole blood, and red blood cells.
[0050] Embodiment 2:
[0051] In order to verify which substance in the plasma the fluorescent probe specifically reacted to with fluorescence, 100 mg / mL concentrations of globulin solution, albumin solution, fibrinogen solution, tyrosine solution, transferrin solution, glucose solution, and electrolyte (sodium chloride saline) were prepared, and 50 μL of each of the above solutions was added to 20 μL of 100 μM TTVP, mixed, and the excitation wavelength was set to 480 nm. The fluorescence signal value at the highest peak (fluorescence emission peak) was measured (n=3). The fluorescence value results showed that the fluorescent probe only had a strong fluorescence response with the albumin solution, and had a certain specificity. Therefore, based on this finding, the fluorescent probe (taking TTVP as an example) can be used as a specific probe for detecting albumin. In addition, within a certain system, the fluorescence intensity increases with the increase of albumin concentration, and has a good linear correlation. For different samples, the statistics of the fluorescence values at the maximum peak are detailed in the table. Figure 4 , the photoluminescence spectra of albumin at different concentrations are shown in Figure 5The results showed that TTVP and TTPy had similar effects and could be used to bind and colorize albumin.
[0052] From the above experimental results, it can be seen that TTVP and TTPy have a specific response phenomenon to albumin in plasma, and can be used for albumin-related detection (such as detection of albumin concentration), and can also be used for detection of coagulation status of blood samples containing albumin.
[0053] Embodiment 3:
[0054] See the detection structure Figure 6 and Figure 7 It includes a base layer 1 made of PMMA, on which a detection channel 3 and a sample addition hole 2 are etched. The detection channel 3 and the sample addition hole 2 are interconnected, and the depth of both is 1mm-5mm (preferably 1mm); the diameter of the sample addition hole 2 is 5mm-10mm (preferably 6mm).
[0055] A protective plate 12 is bonded and covered on the PMMA base layer 1. The protective plate 12 is a circular plate of the same size and concentrically arranged as the PMMA base layer 1. A sample loading port 13 of the same size as the sample loading hole 2 is provided at the center of the protective plate 12 (after the antibodies, red blood cell reagents, fluorescent probes, etc. are coated, the protective plate 12 is fixed). The protective plate 12 is used to protect the sample in the detection channel 3 in the PMMA base layer 1 from splashing out during the rotation process. A connecting ring 14 is bonded below the PMMA base layer 1, and a rotating shaft 15 is rotatably connected to the inside of the connecting ring 14 through a bearing 16. When in use, hold the rotating shaft 15, move the base layer 1 protecting the PMMA to rotate it, and under the centrifugal force and the capillary action of the detection channel 3 and the paper-based chip in the sample loading hole 2, the blood sample flows from the sample loading hole 2 along the detection channel 3 in a direction away from the center. Among them, the bottom of the detection channel 3 and the sample addition hole 2 are paved with paper-based chips, which are in sheet shape, and their contours are adapted to the contours of the bottom of the detection channel 3 and the sample addition hole 2, and the bottom is covered (the bottom of the detection channel 3 and the sample addition hole 2 are both planes). The paper-based chip located at the sample addition hole 2 is circular, and the paper-based chip part facing the positive control group and the detection channel 3 for the reverse typing of the ABO blood type is prepared by plasma separation membrane (cut into a fan shape), the number of the detection channel 3 of the positive control group is one, and the number of the detection channel 3 for the reverse typing of the ABO blood type is two. The material of the paper-based chip facing other channels (a total of seven) is cotton pulp paper (cut into a fan shape), and cotton pulp paper has a mesh structure and the ability to capture cells. The fan-shaped plasma separation membrane (corresponding to 3 detection channels 3) and the fan-shaped cotton pulp paper (corresponding to 7 detection channels 3) are spliced together to form a disc-shaped paper-based chip placed in the sample addition hole 2. The paper-based chips in the detection flow channels 3 (10 in total) are all made of cotton pulp paper.
[0056] The structure of the detection channel 3 is shown in Fig. 9 , including a first straight flow channel 4, a second straight flow channel 5, a third straight flow channel 6, a fourth straight flow channel 7, and a first curved flow channel 9, a second curved flow channel 10, and a third curved flow channel 11, which are connected and have a width of 1mm-5mm (preferably 2mm). The middle of the first straight flow channel 4 is connected to one end of the second straight flow channel 5, one end of the first straight flow channel 4 is connected to the sample addition hole 2, and the other end of the first straight flow channel 4 is connected to one end of the first curved flow channel 9; the other end of the first curved flow channel 9 is connected to the middle of the second straight flow channel 5; the middle of the second straight flow channel 5 is also connected to one end of the third straight flow channel 6, and the other end of the second straight flow channel 5 is connected to one end of the second curved flow channel 10; the other end of the second curved flow channel 10 is connected to the middle of the third straight flow channel 6, and the middle of the third straight flow channel 6 is also connected to one end of the fourth straight flow channel 7; the other end of the fourth straight flow channel 7 is connected to the color development hole 8 (color development part); the other end of the third straight flow channel 6 is connected to one end of the third curved flow channel 11, and the other end of the third curved flow channel 11 is connected to the middle of the fourth straight flow channel 7. The length of the first direct current channel 4, the second direct current channel 5, the third direct current channel 6 and the fourth direct current channel 7 is 10-16mm (preferably, the length of the first direct current channel 4 and the fourth direct current channel 7 is 12mm, and the length of the second direct current channel 5 and the third direct current channel 6 is 15mm). The angle (intersection angle) between the first direct current channel 4 and the second direct current channel 5, the second direct current channel 5 and the third direct current channel 6, and the third direct current channel 6 and the fourth direct current channel 7 is 45-60° (preferably 50°). The connection mode of the direct current channel is further preferably: the middle part of the first direct current channel 4 is connected to the second direct current channel 5, the middle part of the second direct current channel 5 is connected to the third direct current channel 6 and the first curved flow channel 9, the middle part of the third direct current channel 6 is connected to the fourth direct current channel 7 and the second curved flow channel 10, and the middle part of the fourth direct current channel 7 is connected to the third curved flow channel 11. The two ends of the first curved flow channel 9, the second curved flow channel 10, and the third curved flow channel 11 are used to connect the corresponding direct current channels. The diameter of the color development hole 8 (color development part) is 4-8mm (preferably 5mm). In addition, the length L of the detection channel 3 is controlled to be 20-50 mm, and the width W is controlled to be 5-25 mm.
[0057] Use the detection structure under the optimal parameters to carry out subsequent experimental research.
[0058] (1) Embed the cut paper-based chip into the detection channel and sample loading hole on the cut PMMA substrate.
[0059] (2) The following describes the situation of 10 detection channels, which are named 1-10. No. 1 is a positive control group, No. 2-3 is used for ABO blood type reverse typing test, No. 4-5 is used for ABO blood type positive typing test, and No. 6-10 is used for Rh blood type test (or as a rare blood type test, such as MNS, etc.). The schematic diagram of the detection channel allocation can be seen in Figure 8 .
[0060] (3) The detection area (i.e., color development well) of the No. 1 positive control group was coated with 5-30 μL of TTVP solution activated by 99% tetrahydrofuran (TTVP hardly emits light in aqueous solution, which is mainly due to the rotational motion of the molecular rotor consuming the exciton energy and increasing the non-radiative decay rate, resulting in single emission; due to the formation of nanoaggregates, as the THF content increases from 0 to 99%, the photoluminescence PL intensity gradually increases). In subsequent experiments, 20 μL of the prepared 100 μM TTVP solution (prepared with 99% tetrahydrofuran as solvent) was directly added to the color development well of the No. 1 positive control group.
[0061] The detection areas of experimental groups 2 to 10 were coated with 5 to 30 μL of 100 μM TTVP solution. In subsequent experimental studies, the uniform coating volume was 20 μL.
[0062] (4) The first two bends of experimental group 2-3 were coated with 5-30 μL of red blood cell A reagent and 5-30 μL of red blood cell B reagent, respectively. In subsequent experimental studies, the uniform coating volume was 20 μL.
[0063] The material of the sample addition area for reverse typing is a plasma separation membrane, which has the function of automatically separating plasma from whole blood. Therefore, in theory, the plasma mainly flows into the detection channel at the back. The red blood cell A reagent and the red blood cell B reagent can combine with the anti-B antibody and anti-A antibody in the plasma that has been separated by the plasma separation membrane, and then the blood cells will agglutinate, which will affect the ratio of plasma and red blood cells in the sample flowing to the color development hole. The TTVP coated at the color development hole produces different fluorescence response values for samples with different plasma and red blood cell ratios, and the ABO blood typing of the sample is determined by the specific value of the fluorescence value. For example, the plasma in type A blood contains anti-B, which will not react with the pre-coated red blood cell A reagent, and a large amount of plasma will flow to the rear color development hole, producing a strong fluorescence value; it will have a certain agglutination reaction with the pre-coated red blood cell B reagent, and the plasma flowing to the rear color development hole will decrease, and the fluorescence value will be relatively weakened.
[0064] In addition, it was found in actual operation that due to the effects of fluid flow and centrifugation, a small number of red blood cells would flow to the rear end of the flow channel along with the plasma. However, due to the influence of the reticular structure of the paper-based fibers, a small number of red blood cells would remain near the third bend and would not reach the color development area, thus not affecting the fluorescence response of the plasma and TTVP.
[0065] (5) The first two bends of experimental group 4-5 were coated with 5-30 μL anti-A reagent and 5-30 μL anti-B reagent, respectively, and 5-15 μL 0.2% chitosan was added to the antibody reagent to improve the hydrophilicity of the paper base. In subsequent experimental studies, the uniform coating volume was 20 μL. The addition amount of 0.2% chitosan was uniformly 10 μL.
[0066] Anti-A reagents and anti-B reagents can bind to red blood cells expressing corresponding surface antigens, thereby affecting the ratio of plasma to red blood cells in the sample flowing to the color development well. The TTVP coated in the color development well produces different fluorescence response values for samples with different plasma to red blood cell ratios, and the ABO blood typing of the sample is determined by the specific value of the fluorescence value.
[0067] (6) The first two bends of experimental groups 6-10 were coated with 5-30 μL of anti-D, anti-C, anti-c, anti-E, and anti-e reagents, respectively. In subsequent experimental studies, the uniform coating volume was 20 μL. Anti-D, anti-C, anti-c, anti-E, and anti-e reagents can bind to red blood cells expressing corresponding surface antigens, thereby affecting the ratio of plasma and red blood cells in the sample flowing to the color development well. The TTVP coated at the color development well produces different fluorescence response values for samples with different plasma and red blood cell ratios, and the Rh blood typing of the sample is determined by the specific numerical value of the fluorescence value.
[0068] The red blood cell A reagent, red blood cell B reagent, anti-A reagent, anti-B reagent, anti-D, anti-C, anti-C, anti-E, and anti-E reagent mentioned above are all conventional reagents for blood type detection in the prior art and can be purchased directly. In this experimental study, the above reagents were purchased from Jiangsu Zhongji Wantai Company.
[0069] (7) Add 300-1000 μL of diluted whole blood (500 μL was used in subsequent experiments) to the sample loading area (sample loading hole) of the paper base, and dilute it with 0.9% saline at a ratio of 1:1. Then rotate the disk and keep rotating for 1 minute. The rotation speed is controlled at 500-1200 rpm.
[0070] (8) Place the paper-based test card in a portable fluorescence detection device and measure the fluorescence value of the test area in a light-proof environment.
[0071] The determination method for the test results is shown in Table 1 and Table 2:
[0072] Table 1: Comparison table of fluorescence value and ABO blood type (+++: fluorescence value 1500-2500; ++: fluorescence value 1000-1400; +: fluorescence value 400-800)
[0073]
[0074] Table 2: Comparison table of fluorescence value and Rh blood type (+++: fluorescence value 1500-2500; ++: fluorescence value 1000-1400; +: fluorescence value 400-800)
[0075]
[0076] The judgment criteria shown in Table 1 and Table 2 are as follows:
[0077] The four detection channels of ABO reverse typing and ABO positive typing are used to determine the ABO blood type.
[0078] When the fluorescence value of the color developing well of the detection flow channel coated with red blood cell A reagent is 1500-2500, the fluorescence value of the color developing well of the detection flow channel coated with red blood cell B reagent is 1000-1400, the fluorescence value of the color developing well of the detection flow channel coated with anti-A reagent is 1500-2500, and the fluorescence value of the color developing well of the detection flow channel coated with anti-B reagent is 400-800, then the sample is judged to be type A blood.
[0079] When the fluorescence value of the color developing well of the detection flow channel coated with red blood cell A reagent is 1000-1400, the fluorescence value of the color developing well of the detection flow channel coated with red blood cell B reagent is 1500-2500, the fluorescence value of the color developing well of the detection flow channel coated with anti-A reagent is 400-800, and the fluorescence value of the color developing well of the detection flow channel coated with anti-B reagent is 1500-2500, then the sample is judged to be type B blood.
[0080] When the fluorescence value of the color developing well of the detection flow channel coated with red blood cell A reagent is 1000-1400, the fluorescence value of the color developing well of the detection flow channel coated with red blood cell B reagent is 1000-1400, the fluorescence value of the color developing well of the detection flow channel coated with anti-A reagent is 1500-2500, and the fluorescence value of the color developing well of the detection flow channel coated with anti-B reagent is 1500-2500, then the sample is judged to be AB type blood.
[0081] When the fluorescence value of the color developing well of the detection flow channel coated with red blood cell A reagent is 1500-2500, the fluorescence value of the color developing well of the detection flow channel coated with red blood cell B reagent is 1500-2500, the fluorescence value of the color developing well of the detection flow channel coated with anti-A reagent is 400-800, and the fluorescence value of the color developing well of the detection flow channel coated with anti-B reagent is 400-800, then the sample is judged to be type O blood.
[0082] For Rh blood type testing, five detection channels coated with anti-D, anti-C, anti-c, anti-E, and anti-e reagents are used.
[0083] When the fluorescence value of the color developing well of the detection flow channel coated with the anti-D reagent is 1500-2500, the sample is judged to be Rh D positive; when the fluorescence value of the color developing well of the detection flow channel coated with the anti-D reagent is 400-800, the sample is judged to be Rh D negative.
[0084] When the fluorescence value of the color developing well of the detection flow channel coated with the anti-C reagent is 1500-2500, the sample is judged to be Rh C positive; when the fluorescence value of the color developing well of the detection flow channel coated with the anti-C reagent is 400-800, the sample is judged to be Rh C negative.
[0085] When the fluorescence value of the color development well of the detection flow channel coated with the anti-C reagent is 1500-2500, the sample is judged to be Rh c positive; when the fluorescence value of the color development well of the detection flow channel coated with the anti-C reagent is 400-800, the sample is judged to be Rh c negative.
[0086] When the fluorescence value of the color developing well of the detection flow channel coated with the anti-E reagent is 1500-2500, the sample is judged to be Rh E positive; when the fluorescence value of the color developing well of the detection flow channel coated with the anti-E reagent is 400-800, the sample is judged to be Rh E negative.
[0087] When the fluorescence value of the color developing well of the detection flow channel coated with the anti-e reagent is 1500-2500, the sample is judged to be Rhee positive; when the fluorescence value of the color developing well of the detection flow channel coated with the anti-e reagent is 400-800, the sample is judged to be Rhee negative.
[0088] If the above test results are not presented, re-testing is required. If the above test results still cannot be presented after re-testing, it is recommended to replace the test equipment or method.
[0089] Take ABO blood type A, Rh D positive sample as an example, add the above equipment for detection, the fluorescence value of each color development hole of the flow channel is as follows Fig.10 Combining the judgment criteria of Table 1 and Table 2, the sample is blood type A, Rh D positive, Rh C negative, Rh C positive, Rh E negative and Rh E positive.
[0090] Embodiment 4:
[0091] Construct a single bend (see the test channel structure for details) Fig.11 ), double bend (see the flow channel structure for details) Fig.12 ), three bends (see the flow channel structure for details) Fig. 9 ) and direct flow channel (see the flow channel structure for details) Fig.13, length 30mm) of the detection flow channel model, using the preferred parameters in Example 3, the intersection angle is set to 50°. Control the amount of sample added to be consistent. Taking ABO blood type positive typing as an example, the same dose of anti-A reagent is coated at the bends, and the detection area is pre-coated with the same sample amount of TTVP fluorescent probe. Among them, for the three-bend model, the antibody A reagent is coated at the first two bends; for the double-bend model, the anti-A reagent is coated at both bends; for the single-bend model, the anti-A reagent is coated at one bend; for the straight channel model, the anti-A reagent is coated at 1 / 3 and 2 / 3 of its straight pipe. At the same time, 0.2% chitosan is also added to the anti-A reagent to enhance the affinity of the paper base. The amount of anti-A reagent added is the same as in Example 3.
[0092] The red blood cells (type A) in the sample are mixed with antibodies through the bends, the excitation wavelength is set to 480nm, and the fluorescence value at the maximum peak of the detection area is measured. From the results in the table below, it can be found that the antibodies and red blood cells cannot be fully mixed in the straight channel, single bend, and double bends, and the antibodies are not enough to completely capture the number of red blood cells in the sample. Therefore, a small amount of red blood cells in the detection area are mixed with plasma, which affects the fluorescence intensity of TTVP and causes the final fluorescence value to be lower than the theoretical value. The three-bend channel can ensure that the red blood cells in the sample are completely captured because the first two bends are coated with excessive antibodies and the red blood cells and plasma are fully separated in the third bend. The measured fluorescence value is consistent with the theoretical value. Experimental data can be found in Table 3.
[0093] In summary, since the antibodies and red blood cells cannot be fully mixed in the straight channel, single bend channel, and double bend channel, the antibodies are not enough to completely capture the number of red blood cells in the sample, which can easily lead to false positive or false negative detection, resulting in inaccurate test results.
[0094] Table 3: Test results of different flow channel structures (the results are the range of the results of 5 tests)
[0095] Runner model Fluorescence value (au) Direct current 300-600 Single bend 500-700 Double bend 600-900 Three bends 1500-2500 Theoretical results (liquid phase system) 1600-2600
[0096] Embodiment 5:
[0097] Construct flow channel models with different intersection angles, set to 40°, 45°, 50°, 55° and 60° respectively, and control the amount of sample to be added to be consistent. Fig. 9, only the angles between the first direct current channel 4 and the second direct current channel 5, the second direct current channel 5 and the third direct current channel 6, and the third direct current channel 6 and the fourth direct current channel 7 are changed. Taking ABO blood type positive typing as an example, an excess of anti-A reagent is coated in the first two bends, so that the red blood cells in the sample can be completely captured. The detection area is pre-coated with TTVP fluorescent probe, and the specific operation method can be found in Example 3. The time it takes for the sample to reach the detection area under different intersection angle models is detected respectively. The results in the table below show that an intersection angle of 45°-55° can significantly increase the time it takes for the sample to reach the detection area, thereby shortening the detection time and improving the detection efficiency. See Table 4 for the experimental results.
[0098] Table 4: Test results of flow channel models with different intersection angles (the results are the range values of the results of 5 tests)
[0099] Intersection Angle Time(s) 40° 6-8 45° 5-7 50° 2-4 55° 5-7 60° 7-9
[0100] Embodiment 6:
[0101] Prepare TTVP with five concentration gradients of 20μM, 60μM, 100μM, 140μM, and 180μM, and measure the background signals of the five concentrations of TTVP. Then, take 1.2L of normal whole blood, centrifuge at 2500rpm for 3-5min, take the supernatant and put it into a clean centrifuge tube for later use. Take 5 centrifuge tubes, add 150μL of plasma obtained by centrifugation to each, add 30μL of TTVP solution of different concentrations, mix well, and measure the fluorescence value. The measured background signal and fluorescence value are shown in Table 5. From the results in the table, it can be found that when the concentration of TTVP is 60-100μM, the maximum signal-to-noise ratio is achieved, which is conducive to the accurate interpretation of fluorescence value.
[0102] Table 5: TTVP concentration and signal-to-noise ratio
[0103] Concentration (μM) Fluorescence value (au) Background fluorescence (au) Signal-to-Noise Ratio 20 700 50 14.0 60 1100 70 15.7 100 1500 90 16.7 140 1600 110 14.5 180 1650 130 12.7
[0104] Embodiment 7:
[0105] Prepare FITC solution, ICG solution and TTVP solution with a concentration of 100 μM, take 30 μL of each solution and add them to three centrifuge tubes containing 200 μL of whole blood, mix them well, and measure the corresponding fluorescence signal values. The results show that only the fluorescent probe TTVP can produce fluorescence response with whole blood, while ICG and FITC do not have the above phenomenon. Therefore, TTVP has good specificity for detecting blood type and protein. ICG and FITC are not aggregated luminescent materials, but two commonly used fluorescent probes in biological detection. They cannot effectively aggregate with proteins in plasma to produce aggregated luminescent effects.
[0106] The above is only an embodiment of the present invention, and the common knowledge such as the known specific technical solutions and / or characteristics in the solution is not described in detail here. It should be pointed out that for those skilled in the art, without departing from the technical solution of the present invention, several modifications and improvements can be made, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicality of the patent. The scope of protection required by this application shall be based on the content of its claims, and the specific implementation methods and other records in the specification can be used to interpret the content of the claims.
Claims
1. A structure for pre-transfusion detection based on a fluorescent probe, characterized in that: It includes a detection flow channel; the detection flow channel includes a blood sample mixing flow channel and a color development part which are arranged in sequence according to the flow direction of the blood sample; the blood sample mixing flow channel is coated with a blood type detection reagent, and the color development part is coated with an ionic aggregation-induced luminescence material; The ionic aggregation-induced emission material is TTVP and / or TTPy; The blood typing reagent is one of red blood cell A reagent, red blood cell B reagent, anti-A reagent, anti-B reagent, anti-D reagent, anti-C reagent, anti-c reagent, anti-E reagent and anti-e reagent; A paper-based chip is provided in the detection flow channel; the blood sample mixing flow channel includes ≥3 curved flow channels, and the curved flow channels are arranged in sequence according to the direction of blood sample flow; the blood type detection reagent is coated in the first two curved flow channels; The blood sample mixing flow channel includes a first straight flow channel, a second straight flow channel to an N-1th straight flow channel, and an Nth straight flow channel which are arranged in sequence and connected according to the flow direction of the blood sample; a first curved flow channel is connected between the first straight flow channel and the second straight flow channel, and an N-1th curved flow channel is connected between the N-1th straight flow channel and the Nth straight flow channel; an angle between the N-1th straight flow channel and the Nth straight flow channel is 45-60°; N≥4; When N=4, the middle part of the first direct current channel is connected to one end of the second direct current channel, one end of the first direct current channel is connected to the sample addition hole, and the other end of the first direct current channel is connected to one end of the first curved flow channel; the other end of the first curved flow channel is connected to the middle part of the second direct current channel; the middle part of the second direct current channel is also connected to one end of the third direct current channel, and the other end of the second direct current channel is connected to one end of the second curved flow channel; the other end of the second curved flow channel is connected to the middle part of the third direct current channel, and the middle part of the third direct current channel is also connected to one end of the fourth direct current channel; the other end of the fourth direct current channel is connected to the color development part; the other end of the third direct current channel is connected to one end of the third curved flow channel, and the other end of the third curved flow channel is connected to the middle part of the fourth direct current channel.
2. The structure for pre-transfusion detection based on fluorescent probe according to claim 1, characterized in that: The width of the blood sample mixing channel is 1mm-5mm and the depth is 1mm-5mm; the diameter of the color development part is 4-8mm and the depth is 1mm-5mm; the length of the detection channel is 20mm-50mm and the width is 5mm-25mm.
3. The structure for pre-transfusion detection based on fluorescent probe according to claim 2, characterized in that: The concentration of the ionic aggregation-induced emission material coated in the color development part is 60-100 μM.
4. The structure for pre-transfusion detection based on fluorescent probe according to any one of claims 1 to 3, characterized in that: The detection flow channel is arranged on a rotatable base layer; the number of the detection flow channels is several and they are centrally symmetrically distributed around the center of the base layer; one end of the blood sample mixing flow channel away from the color development part is connected to a sample addition hole.
5. Use of an ionic aggregation-induced emission material in preparing a structure for pre-transfusion detection as claimed in claim 4 or in detecting albumin concentration, characterized in that: The ionic aggregation-induced luminescence material is TTVP and / or TTPy; the ionic aggregation-induced luminescence material is used in the color development part of the structure for pre-transfusion detection; The ionic aggregation-induced luminescence material is used to bind to albumin in a blood sample treated with a blood type detection reagent and generate a fluorescent signal under excitation; the blood type is determined by the value of the fluorescent signal and the type of the blood type detection reagent; The four detection channels of ABO reverse typing and ABO positive typing are used to determine ABO blood type: When the fluorescence value of the color development well of the detection flow channel coated with red blood cell A reagent is 1500-2500, the fluorescence value of the color development well of the detection flow channel coated with red blood cell B reagent is 1000-1400, the fluorescence value of the color development well of the detection flow channel coated with anti-A reagent is 1500-2500, and the fluorescence value of the color development well of the detection flow channel coated with anti-B reagent is 400-800, then the sample is determined to be type A blood; When the fluorescence value of the color development well of the detection flow channel coated with red blood cell A reagent is 1000-1400, the fluorescence value of the color development well of the detection flow channel coated with red blood cell B reagent is 1500-2500, the fluorescence value of the color development well of the detection flow channel coated with anti-A reagent is 400-800, and the fluorescence value of the color development well of the detection flow channel coated with anti-B reagent is 1500-2500, then the sample is determined to be type B blood; When the fluorescence value of the color development well of the detection flow channel coated with red blood cell A reagent is 1000-1400, the fluorescence value of the color development well of the detection flow channel coated with red blood cell B reagent is 1000-1400, the fluorescence value of the color development well of the detection flow channel coated with anti-A reagent is 1500-2500, and the fluorescence value of the color development well of the detection flow channel coated with anti-B reagent is 1500-2500, then the sample is determined to be AB type blood; When the fluorescence value of the color developing well of the detection flow channel coated with the red blood cell A reagent is 1500-2500, the fluorescence value of the color developing well of the detection flow channel coated with the red blood cell B reagent is 1500-2500, the fluorescence value of the color developing well of the detection flow channel coated with the anti-A reagent is 400-800, and the fluorescence value of the color developing well of the detection flow channel coated with the anti-B reagent is 400-800, then the sample is determined to be type O blood; For Rh blood typing, five detection channels coated with anti-D, anti-C, anti-c, anti-E, and anti-e reagents are used: When the fluorescence value of the color development well of the detection flow channel coated with the anti-D reagent is 1500-2500, the sample is judged to be Rh D positive; when the fluorescence value of the color development well of the detection flow channel coated with the anti-D reagent is 400-800, the sample is judged to be Rh D negative; When the fluorescence value of the color development well of the detection flow channel coated with the anti-C reagent is 1500-2500, the sample is judged to be Rh C positive; when the fluorescence value of the color development well of the detection flow channel coated with the anti-C reagent is 400-800, the sample is judged to be Rh C negative; When the fluorescence value of the color development well of the detection flow channel coated with the anti-C reagent is 1500-2500, the sample is judged to be Rh c positive; when the fluorescence value of the color development well of the detection flow channel coated with the anti-C reagent is 400-800, the sample is judged to be Rh c negative; When the fluorescence value of the color development well of the detection flow channel coated with the anti-E reagent is 1500-2500, the sample is judged to be Rh E positive; when the fluorescence value of the color development well of the detection flow channel coated with the anti-E reagent is 400-800, the sample is judged to be Rh E negative; When the fluorescence value of the color developing well of the detection flow channel coated with the anti-e reagent is 1500-2500, the sample is judged to be Rhee positive; when the fluorescence value of the color developing well of the detection flow channel coated with the anti-e reagent is 400-800, the sample is judged to be Rhee negative.
Citation Information
Patent Citations
Blood analysis systems and methods
CN107666961A
Reagent for rapidly detecting blood group antibody titer, preparation method, test strip and application
CN114660305A
Direct anti-human globulin micro-fluidic detection chip card and application thereof in detection of red blood cells
CN115792246A
Fluorescent probe for light-activated targeting endoplasmic reticulum and mitochondria as well as preparation method and application of fluorescent probe
CN116903602A
Methods and compositions for detecting non-hematopoietic cells from a blood sample
US20060252054A1
